Hemophilia: Molecular diagnosis and alternatives of treatment

The haemophilia is a recessive disease tied to the X chromosome that generally men suffer. The genetic preimplantation diagnosis (GPD), the prenatal diagnosis and the molecular diagnosis of the mutations that cause haemophilia, are realized in isolated investigations (researches) in order to do prim...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2007
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23717
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/23717
Palabra clave:
Blood clotting factor 8
Blood clotting factor 9
Immunosuppressive agent
Parvovirus vector
Clinical trial
Diagnostic value
Drug efficacy
Fluorescence in situ hybridization
Gene mutation
Gene transfer
Genetic screening
Hemophilia
Hemophilia a
Hemophilia b
Heterozygote
Human
Immunoadsorption
Nonhuman
Plasmapheresis
Polymerase chain reaction
Prenatal diagnosis
Primary prevention
Promoter region
Quality of life
Review
Short tandem repeat
Single strand conformation polymorphism
Southern blotting
Stem cell transplantation
Unspecified side effect
Viral gene therapy
X chromosome
Genetics
Hemophilia
Therapy
Rights
License
Abierto (Texto Completo)
Description
Summary:The haemophilia is a recessive disease tied to the X chromosome that generally men suffer. The genetic preimplantation diagnosis (GPD), the prenatal diagnosis and the molecular diagnosis of the mutations that cause haemophilia, are realized in isolated investigations (researches) in order to do primary prevention, provide advise to the carriers of the disease and their families, which has allowed to bring to the world children free of this disease and also to improve the quality of life of the affected ones. The hopeful procedures in gene therapy (GT) have shown great effectiveness. The intention is to achieve the normal production of the protein which is absent or it is altered in the affected ones, but at the moment the tests carried out in human beings are stopped. Here are other alternate therapies that although are in phase of investigation, would allow to obtain a production of protein to long term and which have been developed thanks to the understanding of the molecular nature of the coagulation factors. © 2007 Corporación Editora Médica del Valle.